Abstract:[Objective] To compare the clinical outcomes of microfracture combined with platelet-rich plasma (PRP) versus microfrac- ture only for treatment of cartilage lesions. [Methods] The data bases, such as Cochrane Library, PubMed, Web of science, EMBASE, CNKI, Wanfang Data and CBM Data were searched for papers comparing clinical outcomes of microfracture combined with PRP versus microfrac- ture only for cartilage lesions from the setting up to December 2021. After literature screening, quality assessment, and data extraction were conducted to meet the inclusion and exclusion criteria, Rev-Man 5.3 was used to perform the meta-analysis of the parameters related to clinical consequences. [Results] A total of 9 articles were enrolled in this study, involving 307 patients with cartilage lesions, including 158 cases in the PRP group and 149 cases in the non-PRP group. As results of the meta-analysis, the PRP group proved significantly superior to the non- PRP group in term of VAS scores at 6, 12 and 24 months after surgery (P<0.001; P<0.001; P=0.11). The PRP group proved sig- nificantly superior to the non- PRP group in term of IKDC scores at 12 and 24 months after surgery (P<0.001; P<0.001). The PRP group proved significantly superior to the non- PRP group in AOFAS scores at the final follow-up lasted for 21.4 months on a mean (P<0.001). [Conclusion] Microfracture combined with PRP does further relieve joint pain and improve joint function, which plays a role in enhancing the therapeutic effect of microfracture.